BidaskClub downgraded shares of Athersys (NASDAQ:ATHX) from a buy rating to a hold rating in a report issued on Friday, June 22nd.
A number of other research analysts also recently commented on ATHX. Maxim Group restated a buy rating and set a $6.00 price objective on shares of Athersys in a research note on Tuesday, March 13th. Zacks Investment Research raised Athersys from a hold rating to a buy rating and set a $2.25 price target for the company in a research note on Tuesday, April 17th. Finally, ValuEngine upgraded Athersys from a hold rating to a buy rating in a report on Wednesday, May 2nd.
NASDAQ ATHX opened at $1.97 on Friday. The stock has a market capitalization of $267.64 million, a PE ratio of -6.79 and a beta of -0.79. Athersys has a 1-year low of $1.29 and a 1-year high of $3.09.
In other Athersys news, EVP John J. Harrington sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $2.30, for a total value of $34,500.00. Following the completion of the sale, the executive vice president now owns 612,503 shares in the company, valued at approximately $1,408,756.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider William Lehmann, Jr. sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 19th. The stock was sold at an average price of $2.25, for a total value of $67,500.00. Following the completion of the sale, the insider now owns 460,084 shares of the company’s stock, valued at approximately $1,035,189. The disclosure for this sale can be found here. 18.60% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in ATHX. SG Americas Securities LLC bought a new position in shares of Athersys in the 4th quarter worth $108,000. JPMorgan Chase & Co. boosted its position in shares of Athersys by 214.9% in the 1st quarter. JPMorgan Chase & Co. now owns 69,370 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 47,339 shares during the last quarter. Finally, Northern Trust Corp boosted its position in shares of Athersys by 7.1% in the 1st quarter. Northern Trust Corp now owns 1,215,690 shares of the biopharmaceutical company’s stock worth $2,225,000 after purchasing an additional 80,708 shares during the last quarter. 16.87% of the stock is owned by hedge funds and other institutional investors.
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.